DVA vs. FMS, SHC, PGNY, PODD, INCY, RDY, EXAS, SWAV, CRL, and UHS
Should you be buying DaVita stock or one of its competitors? The main competitors of DaVita include Fresenius Medical Care (FMS), Sotera Health (SHC), Progyny (PGNY), Insulet (PODD), Incyte (INCY), Dr. Reddy's Laboratories (RDY), Exact Sciences (EXAS), Shockwave Medical (SWAV), Charles River Laboratories International (CRL), and Universal Health Services (UHS). These companies are all part of the "medical" sector.
Fresenius Medical Care (NYSE:FMS) and DaVita (NYSE:DVA) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk, community ranking and valuation.
Fresenius Medical Care has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, DaVita has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.
DaVita received 88 more outperform votes than Fresenius Medical Care when rated by MarketBeat users. Likewise, 61.81% of users gave DaVita an outperform vote while only 53.94% of users gave Fresenius Medical Care an outperform vote.
In the previous week, DaVita had 8 more articles in the media than Fresenius Medical Care. MarketBeat recorded 12 mentions for DaVita and 4 mentions for Fresenius Medical Care. DaVita's average media sentiment score of 1.75 beat Fresenius Medical Care's score of 0.66 indicating that Fresenius Medical Care is being referred to more favorably in the media.
8.3% of Fresenius Medical Care shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 1.4% of DaVita shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Fresenius Medical Care currently has a consensus price target of $24.00, suggesting a potential upside of 19.40%. DaVita has a consensus price target of $118.50, suggesting a potential downside of 11.24%. Given DaVita's higher probable upside, research analysts plainly believe Fresenius Medical Care is more favorable than DaVita.
DaVita has lower revenue, but higher earnings than Fresenius Medical Care. DaVita is trading at a lower price-to-earnings ratio than Fresenius Medical Care, indicating that it is currently the more affordable of the two stocks.
DaVita has a net margin of 5.70% compared to DaVita's net margin of 2.56%. Fresenius Medical Care's return on equity of 64.42% beat DaVita's return on equity.
Summary
DaVita beats Fresenius Medical Care on 13 of the 18 factors compared between the two stocks.
Get DaVita News Delivered to You Automatically
Sign up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
